ContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement
13. Dezember 2022 08:01 ET
|
ContraFect Corporation
YONKERS, N.Y., Dec. 13, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation
17. Juni 2020 07:30 ET
|
ContraFect Corporation
Phase 2 study results demonstrated the potential clinical benefit of exebacase, when used in addition to existing antibiotics, for the treatment of life-threatening MRSA bacteremia Exebacase Phase...
ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors
15. Juni 2020 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., June 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.
26. Mai 2020 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., May 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants
21. Mai 2020 22:59 ET
|
ContraFect Corporation
YONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants
21. Mai 2020 16:09 ET
|
ContraFect Corporation
YONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect Reports First Quarter 2020 Financial Results and Provides Business Update
15. Mai 2020 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., May 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces Four Abstracts Published in the 30th ECCMID Abstract Book
11. Mai 2020 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., May 11, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces Dr. Roger J. Pomerantz, Chief Executive Officer and Chairman, Invited as Keynote Speaker and Presenter in Maxim’s Infectious Disease Virtual Conference
21. April 2020 07:00 ET
|
ContraFect Corporation
YONKERS, N.Y. , April 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect to Chair and Participate in Virtual Superbugs & Superdrugs 2020 Conference
30. März 2020 05:00 ET
|
ContraFect Corporation
YONKERS, N.Y., March 30, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...